Cancer treatment has improved a lot over the past several years, especially because of immunotherapy. Immunotherapy is a way to help the body’s immune system fight cancer cells. It works differently from older methods like chemotherapy and radiation. Immunotherapy trains the immune system to better find and attack cancer. This gives new hope to patients, especially those with advanced or difficult cancers.
Recent studies have given important information about how immunotherapy can be made better and tailored to each patient. These findings are useful for cancer care teams in the United States, including doctors, medical office managers, and healthcare IT staff. This article looks at new research on immunotherapy, how genes affect treatment, and how AI and automation help improve cancer care.
A large study was led by Assistant Professor Ruishan Liu from the University of Southern California (USC). It looked at data from more than 78,000 cancer patients with 20 different types of cancer. The study focused on immunotherapy, chemotherapy, and targeted therapy. Researchers wanted to find links between gene mutations and treatment results.
The study found almost 800 gene mutations that affect survival rates in cancer patients. Out of these, 95 genes were closely connected to differences in survival in cancers like breast, ovarian, skin, and gastrointestinal cancers. This information helps doctors know which gene markers to use for predicting how patients might respond to treatment.
Some gene markers like TP53, CDKN2A, and CDKN2B were strongly linked to treatment success. In lung cancer, especially non-small cell lung cancer (NSCLC), changes in the KRAS gene were linked to worse results with certain drugs called EGFR inhibitors. This means doctors need other treatment options for patients with KRAS mutations.
On the other hand, NF1 gene changes in NSCLC helped patients respond better to immunotherapy but made some targeted therapies less effective. This shows cancer treatment has to be carefully matched to each patient’s genes.
The study also found that mutations in DNA repair genes make tumors less stable. This can improve how well immunotherapy works in lung cancer patients. Patients with changes in immune system signaling genes lived longer when treated with immunotherapy.
These findings were shared in a report by USC in the journal Nature Communications. The researchers built a machine learning model called Random Survival Forest (RSF). This tool predicts how patients will respond to immunotherapy by looking at how different gene mutations interact. It might help doctors pick the best treatment faster and avoid trial and error.
Doctors in the U.S. are using immunotherapy more and more to treat cancers like NSCLC, melanoma, and some cancers of the digestive system. The US Food and Drug Administration (FDA) has approved several new immunotherapy medicines, which gives patients more treatment choices.
For example, pembrolizumab is a drug approved for certain stomach cancers that have a specific marker called PD-L1. It can be used if the cancer scores 1 or higher on the combined positive score (CPS). This means more options for patients who had few treatments before.
Another drug called cabozantinib was approved for some rare tumors in the pancreas and other organs. This shows new cancer treatments are still being developed.
These drug approvals affect how cancer clinics run daily. Clinic managers and IT staff must update billing, insurance claims, and electronic health records to match new treatments. Good coordination helps patients get the right medicine quickly and improves their care.
Cancer clinics in the U.S. face several challenges when adding new immunotherapy treatments. One big problem is making sure patients get tested for biomarkers. Biomarker tests find out who will benefit from certain treatments. But some patients do not get tested or don’t get the right treatment afterward.
Clinic managers need to create procedures to make sure biomarker tests are done on time. This means working with labs, changing patient check-in steps, and training staff to handle complex test results.
Money matters are also important. Immunotherapy drugs can be costly, and billing insurance correctly is complicated. A well-run revenue cycle management system helps clinics stay financially healthy. It handles insurance claims, patient bills, and support programs well.
Some programs, like Merck Helps and Genmab’s MyNavCare, assist patients with paying for medicines. Clinic managers should include these programs in patient services to help patients stick with their treatments and avoid delays.
Another important issue in cancer care is social factors that cause unequal treatment, especially in blood cancers. Social factors include things like income, race, where a person lives, and access to healthcare. Iman Ahmed, PharmD, BCOP, has pointed out that cancer care teams need to be aware of these issues.
Doctors and staff might improve services by helping patients navigate the system better, improving communication, and working with community groups. This helps make sure patients get follow-up care and support. There is a 2025 guide to patient support services that offers ways to reduce barriers and make sure medicines are more accessible to all.
AI and automation are becoming more important in immunotherapy and cancer care. AI helps manage biomarker and genetic testing, scheduling, billing, and patient communication.
For example, AI phone systems like those from Simbo AI handle appointment booking, reminders, and simple questions. This cuts down the work for staff and reduces wait times on calls. Clinics can then serve patients better.
AI tools can also work with electronic health records to find patients who need biomarker tests or qualify for financial help programs. AI looks at patient data all the time and sends alerts if tests or treatments fall behind schedule, helping patients stay on track.
Machine learning models like the RSF from USC researchers help doctors decide on treatments by predicting responses based on gene profiles. These tools support more personalized cancer treatment and better outcomes.
IT staff in cancer clinics must focus on protecting patient data, making sure AI works well with other systems, and following rules like HIPAA. Training staff and planning workflow changes are important to use these technologies smoothly without interrupting care.
New information from meetings like the 2025 ASCO Annual Meeting will keep helping cancer specialists improve care. Updating treatment guidelines and clinic operations to include precision medicine and AI tools will be key.
Understanding gene effects on treatment and using new technology in daily work will help clinics provide better patient care and run more efficiently. Clinics that focus on biomarker testing, financial help, patient support, and automation will be ready for the future of cancer treatment.
Oncology Practice Management aims to offer process solutions for all members of the cancer care team, including medical, surgical, and radiation oncologists, as well as executives, administrators, and billing professionals.
Despite the availability of approved targeted therapies for gastric cancer, there are notable gaps in biomarker testing and the administration of these therapies to patients.
Effective revenue cycle management (RCM) is crucial for healthcare organizations as it helps identify and overcome financial obstacles, ensuring the sustainability of oncology practices.
Elevated levels of Interleukin-6 have been correlated with responses to THIO plus Cemiplimab in treating advanced non-small cell lung cancer (NSCLC), indicating a potential predictive biomarker.
Oncology practices can guide patients to personalized resources and support programs offered by pharmaceutical companies, ensuring they have access to their prescribed medications.
There are comprehensive guides for patient support services that include programs offered by pharmaceutical companies, aiding patients in accessing novel cancer drugs and financial assistance.
The NCCN guidelines provide recently approved first-line treatments for newly diagnosed multiple myeloma patients, both those eligible and ineligible for transplant, enhancing treatment options.
Social determinants of health are critical in understanding health inequities in hematologic malignancies, and providers need to address these disparities to improve patient outcomes.
The 2025 ASCO Annual Meeting, scheduled from May 30 to June 3, 2025, in Chicago, will be significant for oncology professionals to discuss new developments and network.
Studies such as HARMONI-2 demonstrate significant improvements in progression-free survival (PFS) with newer treatments like Ivonescimab compared to traditional therapies like Pembrolizumab.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
